FDA approves new pill combo for resistant breast cancer
The FDA approved a new daily pill combination for advanced breast cancer patients who no longer respond to hormone therapy on Monday.
The treatment pairs giredestrant with everolimus for adults whose tumors carry specific genetic changes. It is for cases where earlier treatments failed to work effectively against the disease progression in body parts where the cancer has spread.
This medication blocks estrogen receptors on cancer cells to stop their growth. It also shuts down separate pathways that allow tumors to continue growing despite previous hormonal interventions designed to stop their expansion.
A trial involving 373 adults showed that those taking the new drug combination progressed a median of ten months before their cancer worsened. This was longer than the five and a half months for standard therapy groups receiving only hormone treatments.
Among patients with the specific mutation, tumors shrank in 27% of those taking the new combination. Only 14% of the comparison group receiving standard hormone therapy alone saw tumors shrink during the study period.
Experts note it remains uncertain if this pairing extends survival time compared to older methods alone. The study results indicate potential benefits for tumor control without confirming longer life spans yet.
“Patients with advanced breast cancer progressing on endocrine therapies often face difficult choices and deteriorating quality of life as options narrow”

